PE20160528A1 - Anticuerpos - Google Patents

Anticuerpos

Info

Publication number
PE20160528A1
PE20160528A1 PE2016000313A PE2016000313A PE20160528A1 PE 20160528 A1 PE20160528 A1 PE 20160528A1 PE 2016000313 A PE2016000313 A PE 2016000313A PE 2016000313 A PE2016000313 A PE 2016000313A PE 20160528 A1 PE20160528 A1 PE 20160528A1
Authority
PE
Peru
Prior art keywords
antibody
binding fragment
same
present
antibodies
Prior art date
Application number
PE2016000313A
Other languages
English (en)
Inventor
Graham Craggs
Diane Marshall
Karine Jeannine Madeleine Herve
Original Assignee
Ucb Biopharma Sprl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49397073&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20160528(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ucb Biopharma Sprl filed Critical Ucb Biopharma Sprl
Publication of PE20160528A1 publication Critical patent/PE20160528A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Abstract

La presente invencion se refiere a un anticuerpo antiCSF- lR y fragmentos de union del mismo, a ADN que codifica para el mismo, a celulas huesped que comprenden dicho ADN y a metodos de expresion del anticuerpo o fragmento de union en una celula huesped. La presente invencion tambien se extiende a composiciones farmaceuticas que comprenden el anticuerpo o un fragmento de union del mismo y al uso del anticuerpo, fragmento de union y composiciones que comprenden el mismo en tratamiento
PE2016000313A 2013-08-30 2014-08-26 Anticuerpos PE20160528A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1315487.7A GB201315487D0 (en) 2013-08-30 2013-08-30 Antibodies

Publications (1)

Publication Number Publication Date
PE20160528A1 true PE20160528A1 (es) 2016-05-21

Family

ID=49397073

Family Applications (2)

Application Number Title Priority Date Filing Date
PE2020000532A PE20201067A1 (es) 2013-08-30 2014-08-26 Anticuerpos anti-csf 1r
PE2016000313A PE20160528A1 (es) 2013-08-30 2014-08-26 Anticuerpos

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PE2020000532A PE20201067A1 (es) 2013-08-30 2014-08-26 Anticuerpos anti-csf 1r

Country Status (39)

Country Link
US (2) US9908939B2 (es)
EP (3) EP4282881A3 (es)
JP (3) JP6632075B2 (es)
KR (1) KR102303130B1 (es)
CN (2) CN105658236B (es)
AR (1) AR097464A1 (es)
AU (1) AU2014314304B2 (es)
BR (1) BR112016004324B1 (es)
CA (1) CA2922240C (es)
CL (1) CL2016000438A1 (es)
CY (1) CY1121964T1 (es)
DK (2) DK3549599T3 (es)
EA (1) EA036255B1 (es)
ES (2) ES2965207T3 (es)
FI (1) FI3549599T3 (es)
GB (1) GB201315487D0 (es)
HK (1) HK1220142A1 (es)
HR (2) HRP20231264T1 (es)
HU (2) HUE064437T2 (es)
IL (1) IL244043B (es)
LT (2) LT3038643T (es)
MA (2) MA44922B1 (es)
MX (1) MX2016002166A (es)
MY (1) MY172484A (es)
NZ (1) NZ717399A (es)
PE (2) PE20201067A1 (es)
PH (1) PH12016500275A1 (es)
PL (2) PL3038643T3 (es)
PT (2) PT3038643T (es)
RS (2) RS64784B1 (es)
SG (1) SG11201601151PA (es)
SI (2) SI3549599T1 (es)
TN (1) TN2016000067A1 (es)
TR (1) TR201909478T4 (es)
TW (1) TWI531582B (es)
UA (1) UA118354C2 (es)
UY (1) UY35718A (es)
WO (1) WO2015028455A1 (es)
ZA (1) ZA201601437B (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201315487D0 (en) * 2013-08-30 2013-10-16 Ucb Pharma Sa Antibodies
WO2016189045A1 (en) * 2015-05-27 2016-12-01 Ucb Biopharma Sprl Method for the treatment of neurological disease
JP2018516933A (ja) * 2015-06-02 2018-06-28 ジェネンテック， インコーポレイテッド 抗ｉｌ−３４抗体を使用して神経学的疾患を治療するための組成物及び方法
EP3471753A1 (en) 2016-06-20 2019-04-24 Kymab Limited Anti-pd-l1 and il-2 cytokines
WO2018183366A1 (en) 2017-03-28 2018-10-04 Syndax Pharmaceuticals, Inc. Combination therapies of csf-1r or csf-1 antibodies and a t-cell engaging therapy
WO2018213665A1 (en) 2017-05-19 2018-11-22 Syndax Pharmaceuticals, Inc. Combination therapies
GB201803226D0 (en) * 2018-02-28 2018-04-11 Ultrahuman Twelve Ltd CSF1R Binding agents
CN109096397B (zh) * 2018-07-18 2019-04-16 博奥信生物技术（南京）有限公司 一种抗人csf-1r单克隆抗体及应用
CN108948198B (zh) * 2018-07-18 2020-09-01 博奥信生物技术（南京）有限公司 抗人csf-1r单克隆抗体及其应用
TWI733274B (zh) * 2018-12-13 2021-07-11 財團法人生物技術開發中心 抗人類csf-1r抗體及其用途
WO2020232051A1 (en) * 2019-05-15 2020-11-19 Biosion Inc. Antibody binding csf-1r and use thereof
CA3162403A1 (en) * 2019-12-24 2021-07-01 Fangyong Du Anti-csf1r molecules and use thereof

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4741900A (en) 1982-11-16 1988-05-03 Cytogen Corporation Antibody-metal ion complexes
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
DK336987D0 (da) 1987-07-01 1987-07-01 Novo Industri As Immobiliseringsmetode
GB8719042D0 (en) 1987-08-12 1987-09-16 Parker D Conjugate compounds
GB8720833D0 (en) 1987-09-04 1987-10-14 Celltech Ltd Recombinant dna product
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
GB8907617D0 (en) 1989-04-05 1989-05-17 Celltech Ltd Drug delivery system
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
WO1992002551A1 (en) 1990-08-02 1992-02-20 B.R. Centre Limited Methods for the production of proteins with a desired function
GB9112536D0 (en) 1991-06-11 1991-07-31 Celltech Ltd Chemical compounds
GB9113120D0 (en) 1991-06-18 1991-08-07 Kodak Ltd Photographic processing apparatus
GB9120467D0 (en) 1991-09-26 1991-11-06 Celltech Ltd Anti-hmfg antibodies and process for their production
FR2716640B1 (fr) 1994-02-28 1996-05-03 Procedes Machines Speciales Dispositif de centrage et de blocage d'une pièce en vue de son rodage à l'aide d'un rodoir à expansion.
US5980898A (en) 1996-11-14 1999-11-09 The United States Of America As Represented By The U.S. Army Medical Research & Material Command Adjuvant for transcutaneous immunization
GB9625640D0 (en) 1996-12-10 1997-01-29 Celltech Therapeutics Ltd Biological products
GB9812545D0 (en) 1998-06-10 1998-08-05 Celltech Therapeutics Ltd Biological products
US6908963B2 (en) 2001-10-09 2005-06-21 Nektar Therapeutics Al, Corporation Thioester polymer derivatives and method of modifying the N-terminus of a polypeptide therewith
GB0129105D0 (en) 2001-12-05 2002-01-23 Celltech R&D Ltd Expression control using variable intergenic sequences
CA2507004A1 (en) 2002-12-03 2004-06-17 Celltech R & D Limited Assay for identifying antibody producing cells
GB0312481D0 (en) 2003-05-30 2003-07-09 Celltech R&D Ltd Antibodies
DK1644412T4 (en) 2003-07-01 2018-11-12 Ucb Biopharma Sprl MODIFIED ANTIBODY-FAB FRAGMENTS
GB0315450D0 (en) 2003-07-01 2003-08-06 Celltech R&D Ltd Biological products
GB0315457D0 (en) 2003-07-01 2003-08-06 Celltech R&D Ltd Biological products
WO2005014655A2 (en) 2003-08-08 2005-02-17 Fresenius Kabi Deutschland Gmbh Conjugates of hydroxyalkyl starch and a protein
AR045563A1 (es) * 2003-09-10 2005-11-02 Warner Lambert Co Anticuerpos dirigidos a m-csf
GB0411186D0 (en) 2004-05-19 2004-06-23 Celltech R&D Ltd Biological products
GB0412181D0 (en) 2004-06-01 2004-06-30 Celltech R&D Ltd Biological products
MY146381A (en) * 2004-12-22 2012-08-15 Amgen Inc Compositions and methods relating relating to anti-igf-1 receptor antibodies
GB0619291D0 (en) 2006-09-29 2006-11-08 Ucb Sa Altered antibodies
TWI595005B (zh) * 2007-08-21 2017-08-11 安健股份有限公司 人類ｃ－ｆｍｓ抗原結合蛋白質
WO2009040562A1 (en) 2007-09-26 2009-04-02 Ucb Pharma S.A. Dual specificity antibody fusions
JO3240B1 (ar) * 2007-10-17 2018-03-08 Janssen Pharmaceutica Nv c-fms مثبطات كيناز
US8470977B2 (en) * 2008-03-14 2013-06-25 Transgene S.A. Antibody against the CSF-1R
DK2262836T3 (da) 2008-03-14 2016-04-04 Transgene Sa Antistof mod CSF-1R
SI2334705T1 (sl) 2008-09-26 2017-05-31 Ucb Biopharma Sprl Biološki produkti
WO2011030107A1 (en) 2009-09-10 2011-03-17 Ucb Pharma S.A. Multivalent antibodies
GB0920127D0 (en) 2009-11-17 2009-12-30 Ucb Pharma Sa Antibodies
AU2010329934B2 (en) * 2009-12-10 2015-05-14 F. Hoffmann-La Roche Ag Antibodies binding preferentially human CSF1R extracellular domain 4 and their use
GB201000467D0 (en) 2010-01-12 2010-02-24 Ucb Pharma Sa Antibodies
MX2012010014A (es) 2010-03-05 2012-09-21 Hoffmann La Roche Anticuerpos contra csf-1r humano y sus usos.
BR112012022046A2 (pt) 2010-03-05 2017-02-14 F Hoffamann-La Roche Ag ''anticorpo,composição farmacêutica,ácido nucleico ,vetores de expressão,célula hospedeira e método para a produção de um anticorpo recombinante''.
AR080698A1 (es) 2010-04-01 2012-05-02 Imclone Llc Anticuerpo o fragmento del mismo que especificamente enlaza la variante de csf -1r humano, composicion farmaceutica que lo comprende, su uso para la manufactura de un medicamento util para el tratamiento de cancer y metodo para determinar si un sujeto es candidato para tratamiento de cancer basado e
TWI651331B (zh) * 2010-05-04 2019-02-21 戊瑞治療有限公司 與集落刺激因子１受體（ｃｓｆ１ｒ）結合之抗體類
BR112014012624A2 (pt) * 2011-12-15 2018-10-09 F Hoffmann-La Roche Ag anticorpos, composição farmacêutica, ácido nucleico, vetores de expressão, célula hospedeira, método para a produção de um anticorpo recombinante e uso do anticorpo
GB201315487D0 (en) * 2013-08-30 2013-10-16 Ucb Pharma Sa Antibodies
GB201315486D0 (en) 2013-08-30 2013-10-16 Ucb Pharma Sa Antibodies

Also Published As

Publication number Publication date
HUE064437T2 (hu) 2024-03-28
EA201690503A1 (ru) 2016-06-30
ES2965207T3 (es) 2024-04-11
MA44922B1 (fr) 2020-06-30
CA2922240A1 (en) 2015-03-05
CN112321711A (zh) 2021-02-05
HRP20191051T1 (hr) 2019-09-06
IL244043B (en) 2021-01-31
LT3549599T (lt) 2023-11-10
SG11201601151PA (en) 2016-03-30
DK3549599T3 (en) 2023-10-30
PL3549599T3 (pl) 2024-03-04
JP2016529266A (ja) 2016-09-23
CL2016000438A1 (es) 2016-11-11
BR112016004324B1 (pt) 2024-01-16
US20180162947A1 (en) 2018-06-14
EP3038643B1 (en) 2019-05-01
KR102303130B1 (ko) 2021-09-16
ES2733735T3 (es) 2019-12-02
MA38930A1 (fr) 2017-12-29
US20160200821A1 (en) 2016-07-14
JP2022002523A (ja) 2022-01-11
DK3038643T3 (da) 2019-06-24
KR20160044018A (ko) 2016-04-22
AU2014314304B2 (en) 2019-12-05
EP4282881A3 (en) 2024-02-21
US9908939B2 (en) 2018-03-06
LT3038643T (lt) 2019-07-25
CN105658236B (zh) 2021-03-19
PH12016500275B1 (en) 2016-05-02
AU2014314304A1 (en) 2016-03-17
CY1121964T1 (el) 2020-10-14
TR201909478T4 (tr) 2019-07-22
AR097464A1 (es) 2016-03-16
EP3038643A1 (en) 2016-07-06
MA44922A1 (fr) 2019-08-30
BR112016004324A2 (pt) 2017-10-24
PT3038643T (pt) 2019-07-25
ZA201601437B (en) 2018-08-29
CA2922240C (en) 2023-09-05
GB201315487D0 (en) 2013-10-16
PL3038643T3 (pl) 2019-11-29
EP3549599A1 (en) 2019-10-09
EP3549599B1 (en) 2023-09-06
TW201512221A (zh) 2015-04-01
EA036255B1 (ru) 2020-10-20
PH12016500275A1 (en) 2016-05-02
JP6632075B2 (ja) 2020-01-15
TWI531582B (zh) 2016-05-01
HUE045672T2 (hu) 2020-01-28
MY172484A (en) 2019-11-26
RS64784B1 (sr) 2023-11-30
JP7195237B2 (ja) 2022-12-23
HRP20231264T1 (hr) 2024-02-02
JP2020005652A (ja) 2020-01-16
TN2016000067A1 (en) 2017-07-05
MX2016002166A (es) 2016-06-23
IL244043A0 (en) 2016-04-21
PE20201067A1 (es) 2020-10-19
FI3549599T3 (fi) 2023-10-31
EP4282881A2 (en) 2023-11-29
SI3549599T1 (sl) 2023-12-29
CN105658236A (zh) 2016-06-08
RS59019B1 (sr) 2019-08-30
NZ717399A (en) 2021-12-24
UA118354C2 (uk) 2019-01-10
SI3038643T1 (sl) 2019-08-30
HK1220142A1 (zh) 2017-04-28
PT3549599T (pt) 2023-11-21
WO2015028455A1 (en) 2015-03-05
UY35718A (es) 2015-03-27
US10421814B2 (en) 2019-09-24

Similar Documents

Publication Publication Date Title
PE20160528A1 (es) Anticuerpos
CY1121934T1 (el) Αντισωματα anti-fcrn
CY1122214T1 (el) Αντισωματα ειδικα για ton fcrn
CO2018012513A2 (es) Anticuerpos
BR112018071276A2 (pt) anticorpos anti-il-33, composições, métodos e usos dos mesmos
BR112014028785A2 (pt) proteínas de ligação a antígeno de st2
CL2015000431A1 (es) Anticuerpos y vacunas para utilizarse en el tratamiento de cánceres por ror1 y para inhibir la metástasis.
AR090903A1 (es) Anticuerpos e inmunoconjugados anti-pmel17
PE20170772A1 (es) Anticuerpo monoclonal anti-ctla4 o su fragmento de union a antigeno, una composicion farmaceutica y uso
CL2012003094A1 (es) Anticuerpo bivalente aislado o fragmento bivalente del mismo, que actua sobre lrp6 potenciando una señal wnt al agrupar uno o mas receptores lrp6 en presencia de una proteina de union de lrp6; acido nucleico que lo codifica; vector que comprende dicho acido nucleico; composicion farmaceutica que comprende un anticuerpo multivalente anti-lrp6; y su uso para tratar cancer.
BR112017023131A2 (pt) anticorpos anti- fcrn
CL2009000862A1 (es) Anticuerpo aislado, derivados o fragmentos aislados del mismo capaz de unirse a la proteina cd151, composición que lo comprende; ácido nucleico que lo codifica, vector y célula huesped que lo comprenden; procedimiento para preparar dicho anticuerpo; util como medicamento para prevenir o tratar el cáncer.
AR090668A1 (es) Anticuerpo anti-adamts-5, derivados y usos del mismo
UY36617A (es) Proteínas de fusión inmunogénicas para el tratamiento del cáncer
MX2022000242A (es) Anticuerpos contra ticagrelor y metodos de uso.
TR201910413T4 (tr) Benralizumab kullanarak astım semptomlarının iyileştirilmesine yönelik yöntemler.
EA201591898A1 (ru) Антитела, направленные на m-csf
BR112017022635A2 (pt) anticorpo de igf-1r e seu uso para diagnóstico de câncer